Cyclosporine – indications in dermatology Review article
Article Sidebar
Published:
Mar 31, 2025
Keywords:
cyclosporine A, psoriasis, atopic dermatitis
Main Article Content
Abstract
Cyclosporine A is a drug that has been used in clinical practice for over 50 years, but is still underestimated in many aspects. The multitude of clinical experiences related to the use of cyclosporine A, along with excellent knowledge of its safety profile and possible side effects, allows for fully informed and safe use of the drug and selection of a dose appropriate to the patient’s profile. This article presents examples of cyclosporine A use in dermatology.
Article Details
How to Cite
Matusiak, Łukasz. (2025). Cyclosporine – indications in dermatology. Medycyna Faktow (J EBM), 18(1(66), 97-102. https://doi.org/10.24292/01.MF.0125.15
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Reich A, Adamski Z, Chodorowska G et al. Łuszczyca. Rekomendacje diagnostyczno-terapeutyczne Polskiego Towarzystwa Dermatologicznego. Część 2. Dermatol Rev. 2020; 107: 110-37.
2. Dehesa L, Abuchar A, Nuno-Gonzalez A et al. The use of Cyclosporine in Dermatology. J Drugs Dermatol. 2012; 11: 979-87.
3. Colombo MD, Cassano N, Bellia G et al. Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal. 2013; 2013: 805705.
4. Vera MR, Heydendael MD, Phyllis I et al. Methotrexate versus Cyclosporine in Moderate-to-Severe Chronic Plaque Psoriasis. N Engl J Med. 2003; 349: 658-65.
5. Yoon HS, Youn JI. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. J Dermatolog Treat. 2007; 18(5): 286-90.
6. Rademaker M, Agnew K, Andrews M et al. J. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol. 2018; 59: 86-100.
7. Kokuhu T, Fukushima K, Ushigome H et al. Dose Adjustment Strategy of Cyclosporine A in Renal Transplant Patients: Evaluation of Anthropometric Parameters for Dose Adjustment and C0 vs. C2 Monitoring in Japan, 2001-2010. Int J Med Sci. 2013; 10: 1665-73.
8. Leczenie umiarkowanej i ciężkiej postaci łuszczycy plackowatej. https://www.gov.pl/web/zdrowie/programy-lekowe.
9. Wollenberg A, Kinberger M, Arents B et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. J Eur Acad Dermatol Venereol. 2022; 36: 1409-31.
10. Nowicki RJ, Trzeciak M , Kaczmarski M et al. Atopowe zapalenie skóry. Interdyscyplinarne rekomendacje diagnostyczno-terapeutyczne Polskiego Towarzystwa Dermatologicznego, Polskiego Towarzystwa Alergologicznego, Polskiego Towarzystwa Pediatrycznego oraz Polskiego Towarzystwa Medycyny Rodzinnej. Część II. Leczenie ogólne oraz nowe metody terapeutyczne. Dermatol Rev. 2019; 106; 475-85.
11. Otsuka A, Tanioka M, Nakagawa Y et al. Effects of cyclosporine on pruritus and serum IL-31 levels in patients with atopic dermatitis. Eur J Dermatol. 2011; 21(5): 816-7.
12. Goujon C, Viguier M, Staumont-Sallé D et al. Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial. J Allergy Clin Immunol Pract. 2018; 6: 562-9.
13. Leczenie chorych z ciężką postacią atopowego zapalenia skóry. https://www.gov.pl/web/zdrowie/programy-lekowe.
14. Solimani F, Forchhammer S, Schloegl A et al. Lichen planus – a clinical guide. J Dtsch Dermatol Ges. 2021; 19: 864-82.
15. Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020; 9: F1000 Faculty Rev-612.
16. Valeyrie-Allanore L, Wolkenstein P, Brochard L et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010; 163: 847-53.
2. Dehesa L, Abuchar A, Nuno-Gonzalez A et al. The use of Cyclosporine in Dermatology. J Drugs Dermatol. 2012; 11: 979-87.
3. Colombo MD, Cassano N, Bellia G et al. Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal. 2013; 2013: 805705.
4. Vera MR, Heydendael MD, Phyllis I et al. Methotrexate versus Cyclosporine in Moderate-to-Severe Chronic Plaque Psoriasis. N Engl J Med. 2003; 349: 658-65.
5. Yoon HS, Youn JI. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. J Dermatolog Treat. 2007; 18(5): 286-90.
6. Rademaker M, Agnew K, Andrews M et al. J. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol. 2018; 59: 86-100.
7. Kokuhu T, Fukushima K, Ushigome H et al. Dose Adjustment Strategy of Cyclosporine A in Renal Transplant Patients: Evaluation of Anthropometric Parameters for Dose Adjustment and C0 vs. C2 Monitoring in Japan, 2001-2010. Int J Med Sci. 2013; 10: 1665-73.
8. Leczenie umiarkowanej i ciężkiej postaci łuszczycy plackowatej. https://www.gov.pl/web/zdrowie/programy-lekowe.
9. Wollenberg A, Kinberger M, Arents B et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. J Eur Acad Dermatol Venereol. 2022; 36: 1409-31.
10. Nowicki RJ, Trzeciak M , Kaczmarski M et al. Atopowe zapalenie skóry. Interdyscyplinarne rekomendacje diagnostyczno-terapeutyczne Polskiego Towarzystwa Dermatologicznego, Polskiego Towarzystwa Alergologicznego, Polskiego Towarzystwa Pediatrycznego oraz Polskiego Towarzystwa Medycyny Rodzinnej. Część II. Leczenie ogólne oraz nowe metody terapeutyczne. Dermatol Rev. 2019; 106; 475-85.
11. Otsuka A, Tanioka M, Nakagawa Y et al. Effects of cyclosporine on pruritus and serum IL-31 levels in patients with atopic dermatitis. Eur J Dermatol. 2011; 21(5): 816-7.
12. Goujon C, Viguier M, Staumont-Sallé D et al. Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial. J Allergy Clin Immunol Pract. 2018; 6: 562-9.
13. Leczenie chorych z ciężką postacią atopowego zapalenia skóry. https://www.gov.pl/web/zdrowie/programy-lekowe.
14. Solimani F, Forchhammer S, Schloegl A et al. Lichen planus – a clinical guide. J Dtsch Dermatol Ges. 2021; 19: 864-82.
15. Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020; 9: F1000 Faculty Rev-612.
16. Valeyrie-Allanore L, Wolkenstein P, Brochard L et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010; 163: 847-53.